Synthesis of α3β4 Nicotinic Acetylcholine Receptor Modulators Derived from Aristoquinoline that Reduce Reinstatement of Cocaine-Seeking Behavior

Le résumé fourni par la source

Growing evidence suggests that inhibition of α3β4 nicotinic acetylcholine receptors (nAChRs) represents a promising therapeutic strategy to treat cocaine use disorder. Recently, aristoquinoline (1), a quinoline-containing alkaloid from Aristotelia chilensis, was identified as an α3β4-selective nAChR inhibitor. Here, we prepared a collection of derivatives of 1 and evaluated their ability to inhibit the α3β4 nAChRs. These studies revealed structure-activity trends that led to the identification of several compounds with increased potency at the α3β4 nAChR and few off-target liabilities. Additional mechanistic studies indicated that these compounds inhibit α3β4 nAChRs in a non-competitive manner but do not act as channel blockers, suggesting they are negative allosteric modulators of the α3β4 nAChR. Finally, using a cocaine-primed reinstatement paradigm, we demonstrated that 1 significantly attenuates drug-seeking behavior in an animal model of cocaine relapse. The results from these studies further support a role for α3β4 nAChR in the addictive properties of cocaine and highlight the possible utility of aristoquinoline derivatives in treating cocaine use disorder.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.